RVTY – Revvity Inc

RVTY — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

7.49

Margin Of Safety %

Put/Call OI Ratio

0.43

EPS Next Q Diff

-3.66

EPS Last/This Y

3.18

EPS This/Next Y

0.58

Price

111.15

Target Price

113.14

Analyst Recom

2.4

Performance Q

32.48

Upside

-58.2%

Beta

1.07

Ticker: RVTY

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	RVTY	100.41	0.50	0.00	1977
2026-06-03	RVTY	101.11	0.50	0.50	1971
2026-06-04	RVTY	102.35	0.50	0.00	1970
2026-06-05	RVTY	98.4	0.50	25.00	1974
2026-06-08	RVTY	100.32	0.51	0.14	1987
2026-06-09	RVTY	104.1	0.50	0.27	2003
2026-06-10	RVTY	101.29	0.51	1.89	2014
2026-06-11	RVTY	101.51	0.51	0.30	2014
2026-06-12	RVTY	99.68	0.51	0.00	2018
2026-06-15	RVTY	100.54	0.51	0.15	2020
2026-06-16	RVTY	101.23	0.50	0.33	2033
2026-06-17	RVTY	97.86	0.50	0.06	2028
2026-06-18	RVTY	99.95	0.50	1.60	2017
2026-06-22	RVTY	98.92	0.52	0.14	1481
2026-06-23	RVTY	99.87	0.51	2.00	1495
2026-06-24	RVTY	105.74	0.51	0.19	1498
2026-06-25	RVTY	113.59	0.50	0.01	1514
2026-06-26	RVTY	112.96	0.41	1.14	1805
2026-06-29	RVTY	111.17	0.43	1.00	1828
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-01	RVTY	100.50	3.0	137.7	5.24
2026-06-02	RVTY	100.25	3.0	153.0	5.24
2026-06-03	RVTY	101.11	3.0	157.1	5.24
2026-06-04	RVTY	102.36	3.0	159.3	5.24
2026-06-05	RVTY	98.39	3.0	137.6	5.24
2026-06-08	RVTY	100.36	3.4	162.6	5.25
2026-06-09	RVTY	104.18	3.4	170.4	5.25
2026-06-10	RVTY	101.29	3.4	142.6	5.25
2026-06-11	RVTY	101.42	3.4	154.6	5.25
2026-06-12	RVTY	99.66	3.4	146.4	5.25
2026-06-15	RVTY	100.56	3.4	157.9	5.25
2026-06-16	RVTY	101.27	3.4	157.1	5.25
2026-06-17	RVTY	97.76	3.4	139.7	5.25
2026-06-18	RVTY	99.94	3.4	163.2	5.25
2026-06-22	RVTY	98.98	3.4	149.8	5.25
2026-06-23	RVTY	99.90	3.3	157.7	5.25
2026-06-24	RVTY	105.64	3.3	178.2	5.25
2026-06-25	RVTY	113.58	3.3	185.7	5.25
2026-06-26	RVTY	113.00	3.3	152.1	5.25
2026-06-29	RVTY	111.15	3.3	147.0	5.25
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	RVTY	-8.00	1.93	8.58
2026-06-03	RVTY	-8.00	1.93	8.58
2026-06-04	RVTY	-8.00	1.93	8.58
2026-06-05	RVTY	-8.00	1.93	8.58
2026-06-08	RVTY	-8.00	1.87	8.58
2026-06-09	RVTY	-8.00	1.87	8.58
2026-06-10	RVTY	-8.00	1.87	7.88
2026-06-11	RVTY	-8.00	1.87	7.88
2026-06-12	RVTY	-8.00	1.87	7.88
2026-06-15	RVTY	-8.00	1.87	7.88
2026-06-16	RVTY	-8.00	1.87	7.88
2026-06-17	RVTY	-8.00	1.87	7.88
2026-06-18	RVTY	-8.00	1.87	7.88
2026-06-22	RVTY	-8.00	1.87	7.88
2026-06-23	RVTY	-7.56	1.87	7.88
2026-06-24	RVTY	-7.43	1.87	7.88
2026-06-25	RVTY	-7.43	1.87	7.88
2026-06-26	RVTY	-7.43	1.87	7.49
2026-06-29	RVTY	-7.43	1.87	7.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

4.97

Avg. EPS Est. Current Quarter

1.22

Avg. EPS Est. Next Quarter

1.31

Insider Transactions

-7.43

Institutional Transactions

1.87

Beta

1.07

Average Sales Estimate Current Quarter

703

Average Sales Estimate Next Quarter

688

Fair Value

111.5

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

45.3

Max Drawdown 5-Year %

-59

Target Price

113.14

P/E

52.69

Forward P/E

19.09

PEG

2.25

P/S

4.27

P/B

1.73

P/Free Cash Flow

25.17

EPS

2.11

Average EPS Est. Cur. Y

5.25

EPS Next Y. (Est.)

5.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.31

Relative Volume

1.45

Return on Equity vs Sector %

-24.3

Return on Equity vs Industry %

-7.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

147

◆ RVTY Healthcare

$111.15

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

8/25

Volume

0/15

Valuation

7/20

TP/AR

1/10

Options

5/10

RSI

65.3

Range 1M

73.7%

Sup Dist

0.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

11/30

Estimates

4/20

Inst/Vol

9/15

Options

6/10

EPS Yr

3.6%

EPS NY

11%

52W%

80.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +8.2% upside

Quality

7/30

Valuation

4/30

Growth

7/25

Stability

8/10

LT Trend

1/5

Upside

+8.2%

Quality

MoS

RVTY — P/E HistoricalDiagnostics & Research

Revvity, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 11000

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

RVTY

Latest News

—

Caricamento notizie per RVTY…

stock quote shares RVTY – Revvity Inc Stock Price stock today

news today RVTY – Revvity Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch RVTY – Revvity Inc yahoo finance google finance

stock history RVTY – Revvity Inc invest stock market

stock prices RVTY premarket after hours

ticker RVTY fair value insiders trading

XGN – Exagen Inc.

XGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

4.55

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

0.03

EPS Last/This Y

0.28

EPS This/Next Y

0.22

Price

4.74

Target Price

8.57

Analyst Recom

Performance Q

77.24

Upside

-748.4%

Beta

2.02

Ticker: XGN

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	XGN	4.85	0.02	0.00	858
2026-06-03	XGN	4.53	0.02	0.00	871
2026-06-04	XGN	4.78	0.02	0.00	872
2026-06-05	XGN	4.29	0.02	1.00	872
2026-06-08	XGN	4.19	0.02	0.00	873
2026-06-09	XGN	4.3	0.02	30.00	878
2026-06-10	XGN	4.18	0.05	0.00	907
2026-06-11	XGN	4.47	0.05	0.00	907
2026-06-12	XGN	4.68	0.05	0.00	933
2026-06-15	XGN	4.58	0.05	1.00	955
2026-06-16	XGN	4.53	0.07	0.17	888
2026-06-17	XGN	4.27	0.07	0.17	888
2026-06-18	XGN	4.53	0.07	0.00	898
2026-06-22	XGN	4.41	0.07	0.00	898
2026-06-23	XGN	4.35	0.03	0.00	686
2026-06-24	XGN	4.53	0.03	0.00	687
2026-06-25	XGN	4.65	0.03	999.99	689
2026-06-26	XGN	4.59	0.06	0.00	710
2026-06-29	XGN	4.75	0.06	999.99	711
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-01	XGN	5.35	-8.1	0.5	-0.65
2026-06-02	XGN	4.82	-8.1	2.8	-0.65
2026-06-03	XGN	4.53	-8.1	2.3	-0.65
2026-06-04	XGN	4.78	-8.1	0.7	-0.65
2026-06-05	XGN	4.30	-8.1	2.9	-0.65
2026-06-08	XGN	4.20	-8.1	1.9	-0.65
2026-06-09	XGN	4.30	-8.1	1.2	-0.65
2026-06-10	XGN	4.19	-8.1	1.9	-0.65
2026-06-11	XGN	4.48	-8.1	0.6	-0.65
2026-06-12	XGN	4.67	-8.1	0.9	-0.65
2026-06-15	XGN	4.58	-8.1	1.8	-0.65
2026-06-16	XGN	4.53	-8.1	1.6	-0.65
2026-06-17	XGN	4.28	-8.1	2.3	-0.65
2026-06-18	XGN	4.53	-8.1	0.7	-0.65
2026-06-22	XGN	4.40	-8.1	1.9	-0.65
2026-06-23	XGN	4.35	-8.1	1.7	-0.65
2026-06-24	XGN	4.53	-8.1	1.0	-0.65
2026-06-25	XGN	4.66	-8.1	1.1	-0.65
2026-06-26	XGN	4.60	-8.1	1.6	-0.65
2026-06-29	XGN	4.74	-8.1	1.1	-0.65
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	XGN	-0.28	-8.90	5.16
2026-06-03	XGN	-0.28	-8.90	5.16
2026-06-04	XGN	-0.28	-8.90	5.16
2026-06-05	XGN	-0.28	-8.90	5.16
2026-06-08	XGN	-0.28	-8.90	5.16
2026-06-09	XGN	-0.28	-8.90	5.16
2026-06-10	XGN	-0.28	-8.90	6.23
2026-06-11	XGN	-0.28	-8.90	6.23
2026-06-12	XGN	-0.28	-8.90	6.21
2026-06-15	XGN	-0.28	-8.91	6.21
2026-06-16	XGN	-0.28	-8.91	6.21
2026-06-17	XGN	-0.28	-8.91	6.21
2026-06-18	XGN	-0.28	-8.91	6.21
2026-06-22	XGN	-0.28	-8.91	6.21
2026-06-23	XGN	-0.28	-8.91	6.21
2026-06-24	XGN	-0.28	-8.91	6.21
2026-06-25	XGN	-0.28	-8.91	6.21
2026-06-26	XGN	-0.28	-8.91	4.55
2026-06-29	XGN	-0.28	-8.91	4.55
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

-0.28

Institutional Transactions

-8.91

Beta

2.02

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

69.7

Max Drawdown 5-Year %

-91.1

Target Price

8.57

P/E

Forward P/E

PEG

P/S

1.68

P/B

7.93

P/Free Cash Flow

EPS

-0.88

Average EPS Est. Cur. Y

-0.65

EPS Next Y. (Est.)

-0.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-29.49

Relative Volume

0.39

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.15

EBIT Estimation

1.1

◆ XGN Healthcare

$4.75

📉

Swing / Pullback

Buy the dip on strong trends

WATCH

Trend

14/20

Pullback

12/25

Volume

11/15

Valuation

12/20

TP/AR

2/10

Options

7/10

RSI

58.2

Range 1M

44.4%

Sup Dist

7.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

9/25

Growth

26/30

Estimates

1/20

Inst/Vol

3/15

Options

5/10

EPS Yr

25.8%

EPS NY

27.2%

52W%

22.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +80.4% upside

Quality

5/30

Valuation

16/30

Growth

20/25

Stability

3/10

LT Trend

3/5

Upside

+80.4%

Quality

XGN — P/E HistoricalDiagnostics & Research

Exagen Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 216

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN

Latest News

—

Caricamento notizie per XGN…

stock quote shares XGN – Exagen Inc. Stock Price stock today

news today XGN – Exagen Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch XGN – Exagen Inc. yahoo finance google finance

stock history XGN – Exagen Inc. invest stock market

stock prices XGN premarket after hours

ticker XGN fair value insiders trading

VCYT – Veracyte Inc.

VCYT — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

10.94

Margin Of Safety %

-36

Put/Call OI Ratio

0.16

EPS Next Q Diff

-0.09

EPS Last/This Y

0.98

EPS This/Next Y

0.08

Price

60.17

Target Price

51.1

Analyst Recom

1.55

Performance Q

100.57

Upside

-76.5%

Beta

1.87

Ticker: VCYT

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	VCYT	47.84	0.18	0.10	3631
2026-06-03	VCYT	48.71	0.18	0.07	3759
2026-06-04	VCYT	49.93	0.18	0.06	3811
2026-06-05	VCYT	48.73	0.18	0.06	3804
2026-06-08	VCYT	47.28	0.18	4.71	3808
2026-06-09	VCYT	49.21	0.30	0.00	4144
2026-06-10	VCYT	48.16	0.30	0.00	4149
2026-06-11	VCYT	47.42	0.29	0.25	4163
2026-06-12	VCYT	47.29	0.29	1.18	4171
2026-06-15	VCYT	49.17	0.29	0.00	4146
2026-06-16	VCYT	50.8	0.30	0.04	4113
2026-06-17	VCYT	51.31	0.28	0.02	4275
2026-06-18	VCYT	53.64	0.28	0.02	4296
2026-06-22	VCYT	53.26	0.07	0.01	2663
2026-06-23	VCYT	53.76	0.07	0.00	2722
2026-06-24	VCYT	56.75	0.07	2.00	2728
2026-06-25	VCYT	58.58	0.15	0.21	2915
2026-06-26	VCYT	60.49	0.16	0.10	2908
2026-06-29	VCYT	60.11	0.16	0.01	2911
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-01	VCYT	48.16	-1.1	-4.5	1.82
2026-06-02	VCYT	47.61	-1.1	-9.2	1.82
2026-06-03	VCYT	48.70	-1.1	-6.4	1.82
2026-06-04	VCYT	49.98	-1.1	-5.7	1.82
2026-06-05	VCYT	48.74	-1.6	-10.4	1.82
2026-06-08	VCYT	47.29	-1.6	-10.9	1.82
2026-06-09	VCYT	49.24	-1.6	-4.3	1.82
2026-06-10	VCYT	48.19	-1.6	-10.1	1.82
2026-06-11	VCYT	47.42	-1.6	-9.6	1.82
2026-06-12	VCYT	47.29	-1.6	-8.4	1.82
2026-06-15	VCYT	49.20	-1.6	-4.4	1.82
2026-06-16	VCYT	50.81	-1.6	-5.1	1.82
2026-06-17	VCYT	51.28	-1.6	-7.5	1.82
2026-06-18	VCYT	53.63	-1.6	-4.0	1.82
2026-06-22	VCYT	53.22	-1.6	-8.8	1.82
2026-06-23	VCYT	53.76	-1.6	-7.2	1.82
2026-06-24	VCYT	56.76	-1.6	-3.1	1.82
2026-06-25	VCYT	58.52	-1.6	-5.3	1.82
2026-06-26	VCYT	60.51	-1.6	-5.2	1.82
2026-06-29	VCYT	60.17	-1.6	-8.5	1.82
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	VCYT	-8.27	3.13	11.05
2026-06-03	VCYT	-8.27	3.13	11.05
2026-06-04	VCYT	-8.27	3.13	11.05
2026-06-05	VCYT	-13.42	3.13	11.05
2026-06-08	VCYT	-13.42	3.07	11.06
2026-06-09	VCYT	-12.53	3.07	11.06
2026-06-10	VCYT	-12.53	3.07	9.47
2026-06-11	VCYT	-12.53	3.07	9.47
2026-06-12	VCYT	-12.53	3.07	9.47
2026-06-15	VCYT	-12.53	0.83	9.47
2026-06-16	VCYT	-12.53	0.83	9.47
2026-06-17	VCYT	-12.53	0.83	9.47
2026-06-18	VCYT	-12.14	0.83	9.47
2026-06-22	VCYT	-12.14	0.84	9.47
2026-06-23	VCYT	-11.96	0.84	9.47
2026-06-24	VCYT	-11.96	0.84	9.47
2026-06-25	VCYT	-11.96	0.84	9.47
2026-06-26	VCYT	-11.96	0.84	10.94
2026-06-29	VCYT	-11.96	0.84	10.94
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

0.43

Avg. EPS Est. Next Quarter

0.43

Insider Transactions

-11.96

Institutional Transactions

0.84

Beta

1.87

Average Sales Estimate Current Quarter

144

Average Sales Estimate Next Quarter

148

Fair Value

38.21

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.1

Max Drawdown 5-Year %

-71.5

Target Price

51.1

P/E

55.41

Forward P/E

31.78

PEG

8.85

P/S

8.87

P/B

3.57

P/Free Cash Flow

30.92

EPS

1.09

Average EPS Est. Cur. Y

1.82

EPS Next Y. (Est.)

1.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

16.25

Relative Volume

1.29

Return on Equity vs Sector %

-21.1

Return on Equity vs Industry %

-4.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.17

EBIT Estimation

-8.5

◆ VCYT Healthcare

$60.19

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

14/20

Pullback

6/25

Volume

4/15

Valuation

3/20

TP/AR

1/10

Options

7/10

RSI

79.8

Range 1M

98.2%

Sup Dist

2.4%

🚀

Momentum Growth

Ride accelerating trends

WATCH

Momentum

17/25

Growth

15/30

Estimates

5/20

Inst/Vol

9/15

Options

10/10

EPS Yr

2.6%

EPS NY

3.7%

52W%

99.2%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🔴 SELL -43.5% upside

Quality

16/30

Valuation

0/30

Growth

10/25

Stability

8/10

LT Trend

4/5

Upside

-43.5%

Quality

MoS

-36%

VCYT — P/E HistoricalBiotechnology

Veracyte, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 755

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT

Latest News

—

Caricamento notizie per VCYT…

stock quote shares VCYT – Veracyte Inc. Stock Price stock today

news today VCYT – Veracyte Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VCYT – Veracyte Inc. yahoo finance google finance

stock history VCYT – Veracyte Inc. invest stock market

stock prices VCYT premarket after hours

ticker VCYT fair value insiders trading

CSTL – Castle Biosciences Inc.

CSTL — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

5.03

Margin Of Safety %

-29

Put/Call OI Ratio

0.22

EPS Next Q Diff

0.2

EPS Last/This Y

-0.56

EPS This/Next Y

0.45

Price

24.34

Target Price

43.56

Analyst Recom

1.11

Performance Q

3.36

Upside

-161.9%

Beta

0.96

Ticker: CSTL

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	CSTL	19.66	0.28	999.99	406
2026-06-03	CSTL	20.37	0.29	0.00	410
2026-06-04	CSTL	21.57	0.29	0.00	409
2026-06-05	CSTL	21.07	0.30	0.00	401
2026-06-08	CSTL	20.13	0.29	0.00	404
2026-06-09	CSTL	21.09	0.29	0.36	405
2026-06-10	CSTL	21.08	0.29	0.00	399
2026-06-11	CSTL	20.98	0.29	0.00	400
2026-06-12	CSTL	20.7	0.29	0.00	400
2026-06-15	CSTL	20.67	0.29	5.00	399
2026-06-16	CSTL	20.44	0.29	0.00	398
2026-06-17	CSTL	20.19	0.27	0.50	416
2026-06-18	CSTL	21.07	0.26	0.25	416
2026-06-22	CSTL	21.19	0.32	0.00	349
2026-06-23	CSTL	21.37	0.32	0.00	349
2026-06-24	CSTL	22.16	0.32	0.92	351
2026-06-25	CSTL	22.93	0.36	0.23	366
2026-06-26	CSTL	24.34	0.23	0.04	342
2026-06-29	CSTL	24.31	0.22	0.40	362
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-01	CSTL	20.93	-100.0	-33.6	-1.36
2026-06-02	CSTL	19.79	-100.0	-29.8	-1.36
2026-06-03	CSTL	20.39	-100.0	-37.1	-1.36
2026-06-04	CSTL	21.58	-100.0	-39.0	-1.36
2026-06-05	CSTL	21.07	-100.0	-32.2	-1.39
2026-06-08	CSTL	20.14	-100.0	-30.7	-1.39
2026-06-09	CSTL	21.06	-100.0	-38.0	-1.39
2026-06-10	CSTL	21.07	-100.0	-34.1	-1.39
2026-06-11	CSTL	20.98	-100.0	-33.8	-1.39
2026-06-12	CSTL	20.71	-100.0	-33.0	-1.39
2026-06-15	CSTL	20.64	-100.0	-33.8	-1.39
2026-06-16	CSTL	20.45	-100.0	-33.4	-1.39
2026-06-17	CSTL	20.18	-100.0	-33.1	-1.39
2026-06-18	CSTL	21.12	-100.0	-37.9	-1.39
2026-06-22	CSTL	21.22	-100.0	-34.7	-1.39
2026-06-23	CSTL	21.38	-100.0	-34.7	-1.39
2026-06-24	CSTL	22.16	-100.0	-37.1	-1.39
2026-06-25	CSTL	22.88	-100.0	-36.7	-1.39
2026-06-26	CSTL	24.31	-100.0	-38.7	-1.39
2026-06-29	CSTL	24.34	-100.0	-34.5	-1.39
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	CSTL	-23.59	-1.18	4.80
2026-06-03	CSTL	-23.59	-1.18	4.80
2026-06-04	CSTL	-24.29	-1.18	4.80
2026-06-05	CSTL	-24.10	-1.18	4.80
2026-06-08	CSTL	-24.10	-1.17	4.80
2026-06-09	CSTL	-24.01	-1.17	4.80
2026-06-10	CSTL	-24.07	-1.17	5.03
2026-06-11	CSTL	-24.07	-1.17	5.03
2026-06-12	CSTL	-24.07	-1.17	5.03
2026-06-15	CSTL	-24.07	-1.14	5.03
2026-06-16	CSTL	-22.79	-1.14	5.03
2026-06-17	CSTL	-22.79	-1.14	5.03
2026-06-18	CSTL	-20.65	-1.14	5.03
2026-06-22	CSTL	-20.11	-1.15	5.03
2026-06-23	CSTL	-20.11	-1.15	5.03
2026-06-24	CSTL	-20.36	-1.15	5.03
2026-06-25	CSTL	-20.36	-1.15	5.03
2026-06-26	CSTL	-20.36	-1.15	5.03
2026-06-29	CSTL	-20.36	-1.15	5.03
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.49

Avg. EPS Est. Current Quarter

-0.4

Avg. EPS Est. Next Quarter

-0.29

Insider Transactions

-20.36

Institutional Transactions

-1.15

Beta

0.96

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

17.39

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

69.2

Max Drawdown 5-Year %

-85

Target Price

43.56

P/E

Forward P/E

PEG

P/S

2.17

P/B

1.6

P/Free Cash Flow

163.19

EPS

-0.43

Average EPS Est. Cur. Y

-1.39

EPS Next Y. (Est.)

-0.93

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3.78

Relative Volume

0.74

Return on Equity vs Sector %

-30.4

Return on Equity vs Industry %

-13.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.21

EBIT Estimation

-34.5

◆ CSTL Healthcare

$24.32

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

14/20

Pullback

6/25

Volume

9/15

Valuation

12/20

TP/AR

2/10

Options

6/10

RSI

Range 1M

99.2%

Sup Dist

4.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

10/25

Growth

16/30

Estimates

2/20

Inst/Vol

2/15

Options

10/10

EPS Yr

-76.5%

EPS NY

36.3%

52W%

34.2%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +14.5% upside

Quality

6/30

Valuation

6/30

Growth

11/25

Stability

8/10

LT Trend

2/5

Upside

+14.5%

Quality

MoS

-29%

CSTL — P/E HistoricalDiagnostics & Research

Castle Biosciences, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 942

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL

Latest News

—

Caricamento notizie per CSTL…

stock quote shares CSTL – Castle Biosciences Inc. Stock Price stock today

news today CSTL – Castle Biosciences Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CSTL – Castle Biosciences Inc. yahoo finance google finance

stock history CSTL – Castle Biosciences Inc. invest stock market

stock prices CSTL premarket after hours

ticker CSTL fair value insiders trading

RVTY – Revvity Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RVTY

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

XGN – Exagen Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: XGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y